Dataset from A 4-week, Randomised, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Tiotropium + Olodaterol Fixed Dose Combination (5/5 µg) Delivered by the Respimat® Inhaler Versus the Free Combination of Tiotropium 5 µg and Olodaterol 5 µg Delivered by Separate Respimat® Inhalers in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This is a 4-week, multicenter, randomized, double-blind, parallel group and active controlled
study.

Patients will be randomized (1 to 1 ratio) to a 4-week double-blind treatment period of
either FDC (fixed-dose combination) of tiotropium + olodaterol (5/5 µg) plus placebo or the
free combination of tiotropium 5 µg and olodaterol 5 µg; all administered via the Respimat®
inhaler. The purpose is to show non-inferiority between the FDC and the free combination of
tiotropium and olodaterol in patients with COPD.